OPTIMIZING OUTPATIENT ANESTHESIA: IMPROVING ANALGESIA AND REDUCING OPIOID MISADVENTURE

优化门诊麻醉:改善镇痛并减少阿片类药物事故

基本信息

  • 批准号:
    9719812
  • 负责人:
  • 金额:
    $ 55.99万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-07-01 至 2021-12-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT The overall long-term objectives of this research are to: (1) reduce the over-prescribing of postoperative discharge opioids which contribute to the population reservoir of unused pills available for patient misuse, and for the diversion and misadventure which are contributing to the devastating public health problem of opioid addiction, overdose, and death; and (2) improve pain treatment, decrease postoperative opioid requirements, increase patient safety, and diminish opioid-related adverse and side effects after outpatient surgery. Our research fundamentally challenges long-practiced yet untested notions that opioids of short duration are the best way to treat surgical pain and to help patients. Anesthesiologists and surgeons face the challenge that surgical pain is inadequately treated in >80% of patients, 10-50% of whom develop chronic postsurgical pain, for which acute postoperative pain is the single greatest risk factor. Opioids are the primary pharmacotherapy for surgical pain, yet with increased use of short-duration opioids, surgical pain treatment has not improved over the past two decades. In contrast, three decades of clinical research and experience shows that a single intraoperative dose of a long-duration opioid (i.e. methadone), which sustains therapeutic drug concentrations, produces better analgesia than repeated doses of short-duration opioids and reduces further opioid requirements, in inpatient surgery. Nevertheless, in outpatient surgery, methadone has never been evaluated, and the potential benefits of methadone in outpatient surgery regarding better postoperative pain, side effects, safety, and reduced opioid consumption remain unrealized. This is a missed opportunity. We will test the innovative, paradigm-shifting hypothesis that in outpatient surgery, intraoperative anesthesia with methadone, compared with conventional short-duration opioids, achieves better analgesia, with similar or diminished side effects, reduces development of chronic postsurgical pain, improves postoperative recovery, and most importantly, decreases postoperative opioid consumption. Demonstrating reduced opioid consumption and hence diminishing prescribing of take-home opioids could shrink the population reservoir of unused opioids available for diversion and misuse, and reduce addiction, overdose, and death. This hypothesis will be tested in two prospective, randomized, double-blind clinical trials, with separate outpatient cohorts of short-stay (overnight <24 hours) and same-day surgery. We will compare general anesthesia with single-dose methadone vs as needed short-duration opioids, evaluate intraoperative and postoperative opioid use, opioid side effects, short-term and long-term postoperative pain, and overall quality of recovery for up to 1 year. Successful completion of the aims portends improved outpatient surgical care, enhanced patient recovery, and reduced postoperative opioid use. An ensuing revolutionary redesign of anesthesia care, and transformational approach to and reduction of postoperative opioid prescribing, would shrink the pool of prescription opioids in America, and help address one of the primary contributory factors to the opioid epidemic.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Evan D. Kharasch其他文献

Scholarly Debate About Drug Efficacy in Scientific Journals Is “Protected Speech,” Not Libel
科学期刊上关于药物疗效的学术争论是“受保护的言论”,而非诽谤
  • DOI:
    10.1016/j.mayocp.2023.12.003
  • 发表时间:
    2024-02-01
  • 期刊:
  • 影响因子:
    6.700
  • 作者:
    Evan D. Kharasch;Paul B. Klaas;William L. Lanier
  • 通讯作者:
    William L. Lanier
META-ANALYSIS OF CYP2D6 METABOLIZER PHENOTYPE AND METOPROLOL PHARMACOKINETICS
CYP2D6代谢表型和美托洛尔药代动力学的荟萃分析
  • DOI:
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Charlene M. Blake;Evan D. Kharasch;Matthias Schwab;Peter Nagele
  • 通讯作者:
    Peter Nagele
Morphine and hydromorphone pharmacokinetics in human volunteers: population-based modelling of interindividual and opioid-related variability
人体志愿者中吗啡和氢吗啡酮的药代动力学:个体间及阿片类相关变异性的基于群体的建模
  • DOI:
    10.1016/j.bja.2024.08.042
  • 发表时间:
    2025-02-01
  • 期刊:
  • 影响因子:
    9.200
  • 作者:
    Konrad Meissner;Erik Olofsen;Albert Dahan;Evan D. Kharasch
  • 通讯作者:
    Evan D. Kharasch
Improved prediction of drug interactions using in vivo Ki
使用体内 Ki 改进药物相互作用的预测
  • DOI:
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Evan D. Kharasch;A. Walker;C. Hoffer;P. Sheffels
  • 通讯作者:
    P. Sheffels
Aerosol propellant interference with clinical mass spectrometers

Evan D. Kharasch的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Evan D. Kharasch', 18)}}的其他基金

OPTIMIZING OUTPATIENT ANESTHESIA: IMPROVING ANALGESIA AND REDUCING OPIOID MISADVENTURE
优化门诊麻醉:改善镇痛并减少阿片类药物事故
  • 批准号:
    10087912
  • 财政年份:
    2018
  • 资助金额:
    $ 55.99万
  • 项目类别:
BIOEQUIVALENCE AND CLINICAL IMPLICATIONS OF GENERIC BUPROPION
仿制药安非他酮的生物等效性和临床意义
  • 批准号:
    8733057
  • 财政年份:
    2013
  • 资助金额:
    $ 55.99万
  • 项目类别:
BIOEQUIVALENCE AND CLINICAL IMPLICATIONS OF GENERIC BUPROPION
仿制药安非他酮的生物等效性和临床意义
  • 批准号:
    8669663
  • 财政年份:
    2013
  • 资助金额:
    $ 55.99万
  • 项目类别:
ADDICTION THERAPY: METABOLISM AND TRANSPORT-MEDIATED DRUG INTERACTIONS
成瘾治疗:代谢和转运介导的药物相互作用
  • 批准号:
    7681770
  • 财政年份:
    2008
  • 资助金额:
    $ 55.99万
  • 项目类别:
ADDICTION THERAPY: METABOLISM AND TRANSPORT-MEDIATED DRUG INTERACTIONS
成瘾治疗:代谢和转运介导的药物相互作用
  • 批准号:
    8286380
  • 财政年份:
    2008
  • 资助金额:
    $ 55.99万
  • 项目类别:
ADDICTION THERAPY: METABOLISM AND TRANSPORT-MEDIATED DRUG INTERACTIONS
成瘾治疗:代谢和运输介导的药物相互作用
  • 批准号:
    7883689
  • 财政年份:
    2008
  • 资助金额:
    $ 55.99万
  • 项目类别:
ADDICTION THERAPY: METABOLISM AND TRANSPORT-MEDIATED DRUG INTERACTIONS
成瘾治疗:代谢和运输介导的药物相互作用
  • 批准号:
    8102080
  • 财政年份:
    2008
  • 资助金额:
    $ 55.99万
  • 项目类别:
ADDICTION THERAPY: METABOLISM AND TRANSPORT-MEDIATED DRUG INTERACTIONS
成瘾治疗:代谢和转运介导的药物相互作用
  • 批准号:
    7578830
  • 财政年份:
    2008
  • 资助金额:
    $ 55.99万
  • 项目类别:
CYP2B6 ACTIVITY AND DRUG EFFECTS
CYP2B6 活性和药物作用
  • 批准号:
    7603378
  • 财政年份:
    2007
  • 资助金额:
    $ 55.99万
  • 项目类别:
CYP3A PROBES AND HEPATIC BLOOD FLOW
CYP3A 探针和肝血流
  • 批准号:
    7603355
  • 财政年份:
    2007
  • 资助金额:
    $ 55.99万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 55.99万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 55.99万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 55.99万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 55.99万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 55.99万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 55.99万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 55.99万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 55.99万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 55.99万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 55.99万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了